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PLD1 Regulates mTOR Signaling
and Mediates Cdc42 Activation of S6K1
Introduction
The mammalian target of rapamycin (mTOR) is a master
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Ping Huang,2 Michael A. Frohman,2
Stephanie J. Walker,3 H. Alex Brown,4 regulator of cell growth and proliferation [1]. mTOR ex-
erts its cellular functions by signaling to multiple down-and Jie Chen1,*
1Department of Cell and Structural Biology stream effectors, the best characterized of which are
the ribosomal S6 kinase 1 (S6K1) and the eukaryoticUniversity of Illinois at Urbana-Champaign
601 S. Goodwin Avenue B107 translation initiation factor 4E binding protein 1 (4E-BP1)
[2, 3]. Both S6K1 and 4E-BP1 are regulated by multisiteUrbana, Illinois 61801
2 Department of Pharmacology and phosphorylation, and both are thought to regulate pro-
tein synthesis at the translation initiation level [2, 3].The Center for Developmental Genetics
University Medical Center at Stony Brook As a member of the phosphatidylinositol kinase-related
kinase family [4], the Ser/Thr protein kinase activity ofStony Brook, New York 11794
3 Department of Cell Biology mTOR is essential for the phosphorylation of S6K1 and
4E-BP1 both in vitro and in vivo [2, 3]. Regulation of theseHarvard Medical School
Boston, Massachusetts 02115 downstream effectors requires at least two upstream
signal inputs. While the mTOR pathway is believed to4 Department of Pharmacology
Vanderbilt University Medical Center sense the availability of amino acids and cellular energy
levels, the phosphatidylinositol-3-kinase (PI3K) pathway412B Preston Research Building
Nashville, Tennessee 37232 transduces mitogenic signals, and the two pathways
converge on S6K1 and 4E-BP1 [2, 3, 5]. The nutrient-
sensing mechanism of mTOR has recently been re-
vealed to involve a protein complex containing the regu-
latory associated protein of mTOR (Raptor) [6, 7] and,Summary
potentially, the tuberous sclerosis complex proteins
TSC1/TSC2 [8].Background: The mammalian target of rapamycin
(mTOR) regulates cell growth and proliferation via the Recently, we have identified the lipid second messen-
ger, phosphatidic acid (PA), as a critical mediator fordownstream targets ribosomal S6 kinase 1 (S6K1) and
eukaryotic translation initiation factor 4E binding protein mitogenic activation of mTOR signaling [9]. An acute
increase of cellular PA level is required for serum stimu-1 (4E-BP1). We have identified phosphatidic acid (PA)
as a mediator of mitogenic activation of mTOR signaling. lation of mTOR signaling toward S6K1 and 4E-BP1, and
PA may directly interact with mTOR and modulate mTOR’sIn this study, we set out to test the hypotheses that
phospholipase D 1 (PLD1) is an upstream regulator of signaling capacity [9]. The synthesis and turnover of
cellular PA can be regulated by several metabolic path-mTOR and that the previously reported S6K1 activation
by Cdc42 is mediated by PLD1. ways, among which the widely distributed phospholi-
pase D (PLD) hydrolyzes phosphatidylcholine to yieldResults: Overexpression of wild-type PLD1 increased
S6K1 activity in serum-stimulated cells, whereas a cata- PA and choline, in response to a variety of extracellular
stimuli [10, 11]. We have indeed observed a concertedlytically inactive PLD1 exerted a dominant-negative ef-
fect on S6K1. More importantly, eliminating endogenous decrease of cellular PA levels and inhibition of mTOR
signaling in cells treated by 1-butanol, an inhibitor ofPLD1 by RNAi led to drastic inhibition of serum-stimu-
lated S6K1 activation and 4E-BP1 hyperphosphorylation PLD-catalyzed PA production [9]. However, as a primary
alcohol, the specificity of butanol’s action is in questionin both HEK293 and COS-7 cells. Knockdown of PLD1
also resulted in reduced cell size, suggesting a critical [12], and direct investigation of PLD’s involvement in
mTOR signaling is required. Upstream pathways thatrole for PLD1 in cell growth control. Using a rapamycin-
can lead to PLD activation include conventional PKC,resistant S6K1 mutant, Cdc42’s action was demon-
ARF, and Rho families of small G proteins [10, 11]. Inter-strated to be through the mTOR pathway. When Cdc42
estingly, activated Cdc42 and Rac1 also potently stimu-was mutated in a region specifically required for PLD1
late S6K1 in vivo [13]. A model has been proposedactivation, its ability to activate S6K1 in the presence
in which membrane recruitment of S6K1 by activatedof serum was hindered. However, when exogenous PA
Cdc42/Rac1 allows phosphorylation and activation ofwas used as a stimulus, the PLD1-inactive Cdc42 mutant
S6K1 by a membrane bound kinase [13]. In light ofbehaved similarly to the wild-type protein.
the potential involvement of PLD in mTOR signaling, aConclusions: Our observations reveal the involvement
mechanism of S6K1 activation through the Rho proteins’of PLD1 in mTOR signaling and cell size control, and
action on PLD should also be considered [14]. Of theprovide a molecular mechanism for Cdc42 activation of
two mammalian PLD proteins, PLD1, but not PLD2, isS6K1. A new cascade is proposed to connect mitogenic
activated by Rho family members via direct interactionsignals to mTOR through Cdc42, PLD1, and PA.
both in vitro and in vivo [15–18].
PLD is mostly associated with vesicular functions [19]
and cytoskeleton reorganization [18, 20]. PLD’s role in*Correspondence: jiechen@uiuc.edu
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in Figure 1B indicated that the recombinant PLD1 pro-
tein contributed significantly to the total cellular PLD
activity in HEK293 cells, which typically have a low basal
and serum-stimulated PLD activity. As previously re-
ported [17], the recombinant PLD1 proteins migrated as
doublets on SDS-PAGE (Figures 1A and 1B).
PLD1 siRNA Inhibits mTOR Signaling to S6K1
and 4E-BP1
A more direct approach was used to examine the re-
quirement of PLD1 in mTOR signaling in which the en-
dogenous PLD1 protein was knocked down by small
interference RNA (siRNA) [25]. When transfected into
HEK293 cells, two siRNAs for PLD1 each reduced the
Figure 1. Overexpression of PLD1 Affects S6K1 Activation
endogenous PLD1 protein level by80% (Figure 2A). An
(A) HEK293 cells were cotransfected with Myc-S6K1 and HA-tagged
siRNA for glyceraldehyde-3-phosphate dehydrogenasewild-type (wt), catalytically inactive (K898R) PLD1, or empty vector.
(GAPDH) served as a negative control. Upon knockdownFollowing serum starvation, the cells were stimulated with serum,
of PLD1, serum-stimulated 4E-BP1 hyperphosphoryla-and the recombinant S6K1 was immunoprecipitated and assayed
in vitro. tion and S6K1 phosphorylation on Thr389 (a putative
(B) Recombinant PLD1 alone was expressed in cells treated as in site for the mTOR kinase [26]) were both markedly dimin-
(A). In vivo transphosphatidylation assays were performed. All the ished (Figure 2A). Consistent with Thr389 phosphoryla-
activities were normalized against that of empty vector transfection
tion being critical for S6K1 activation, the kinase activity(assigned a value of 100% or one). Western blots show the expres-
of S6K1 in PLD1 siRNA-transfected cells was signifi-sion of recombinant proteins.
cantly inhibited (Figure 2B). On the other hand, the pro-
tein levels of mTOR, S6K1, and tubulin were unaffected
in the same cells, confirming the specificity of the siRNAthe regulation of cell proliferation has also been specu-
for PLD1. The serum-activated Erk1/2 phosphorylationlated, but the relevant molecular mechanisms are un-
was also intact in PLD1 siRNA-transfected cells, sug-known. In recent years, intensive studies of cell growth
gesting that in these cells serum activation of MAP ki-and size control in Drosophila have unraveled a major
nase is not dependent on PLD1. Similar observationsinsulin- and nutrient-regulated growth pathway involv-
were made in COS-7 cells, in which the reduction ofing the Drosophila TOR (dTOR), PI3K, and TSC1/2 [1].
PLD1 protein levels by siRNA transfection was accom-Most recently, mTOR has been shown to control cell
panied by drastic inhibition of 4E-BP1 and S6K1 (T389)size [21, 22] by signaling through S6K1 and 4E-BP1 [22,
phosphorylation, as well as a complete suppression of23]. If the mTOR pathway indeed lies downstream of
serum-stimulated S6K1 activity (Figures 2A and 2B).PLD, it would provide a molecular link between PLD
Taken together, our data strongly suggest that PLD1 isfunction and cell growth. In this report, we investigate
an upstream component in the mTOR pathway, mediat-the putative pathway of PLD1-PA-mTOR-S6K1/4E-BP1.
ing mitogenic signals to activate mTOR downstreamOur data provide strong evidence for the involvement
signaling.of PLD1 in mitogenic activation of S6K1 and phosphory-
lation of 4E-BP1, and reveal an essential role for PLD1
in cell growth control. In addition, our findings support PLD1 siRNA Reduces Proliferating Cell Size
a model in which Cdc42 activates S6K1 through PLD1 mTOR regulates cell growth by controlling cell size
and PA. through its signaling to S6K1 and 4E-BP1 [21–23]. To
directly investigate PLD1’s possible role in the regula-
tion of cell growth, we examined the effect of PLD1Results
siRNA on the size of proliferating cells by measuring the
parameter mean forward scatter height (mean FSC-H)Overexpression of Recombinant PLD1 Affects
S6K1 Activation with a flow cytometer. Rapamycin treatment of COS-7
cells led to a left-shift of the mean FSC-H distributionTo probe PLD1’s potential involvement in mTOR signal-
ing, we used S6K1 activation as a readout to examine (Figure 3A) that corresponded to 15% decrease in
average cell size (Figure 3B), which is slightly more pro-the effect of PLD1 overexpression. HA-tagged PLD1 and
Myc-tagged S6K1 were coexpressed in HEK293 cells, nounced than those observed in other cell types [21, 22].
Compared to mock-transfected cells, transfection ofand the activation of recombinant S6K1 by serum was
assayed. Expression of the wild-type PLD1 led to an PLD1 siRNA led to a reduction of size by 7% in these
cells (Figures 3A and 3B). The potential problem of cellu-increase in S6K1 activity by 1.5-fold (Figure 1A), con-
sistent with the notion that PLD1 may be an upstream lar toxicity as a result of RNA transfection was excluded
by the observation that the GAPDH siRNA, transfectedregulator of mTOR signaling. The catalytically inactive
mutant PLD1K898R [24] conferred a modest dominant- under identical conditions, did not affect the cell size.
Initial experiments indicated that the two PLD1 siRNAsnegative effect on S6K1 (Figure 1A), suggesting a re-
quirement of PA production via PLD1 catalytic activity had similar effects on cell size (data not shown). siRNA1
was subsequently used in several independent experi-in the mTOR pathway. In vivo PLD activity was measured
by transphosphatidylation assays, and the results shown ments, which yielded the data shown in Figure 3. The cell
Regulation of mTOR Signaling by PLD1 and Cdc42
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Figure 2. PLD1 siRNA Inhibits S6K1 Activation
(A) HEK293 (left) or COS-7 cells (right) were transfected with PLD1 siRNA1, siRNA2, a control siRNA (GAPDH), or OligoFectamine alone, as
described in Experimental Procedures. Upon serum starvation and stimulation, the cells were lysed and subjected to Western analysis with
various antibodies. “P” denotes phosphorylation. Phosphorylation of S6K1 and Erk1/2 was assessed by phosphospecific antibodies, and 4E-
BP1 phosphorylation was revealed by slower migration of the protein bands.
(B) Endogenous S6K1 was immunoprecipitated and assayed in vitro. Relative S6K1 activities are shown, with those without serum stimulation
assigned a value of one.
cycle phase distribution of the asynchronously cycling Although the degree of size reduction was less than
that in COS-7 cells, the observed effect in HEK293 wascells was not affected by rapamycin treatment or trans-
fection of siRNA, and the size reduction was observed nonetheless statistically significant. Rapamycin treat-
ment led to10% reduction in cell size, and cells trans-in both G1 and G2/M populations (data not shown). Data
shown in Figure 3B are average mean FSC-H for the fected with PLD1 siRNA were 5% smaller than the
control cells (Figure 3B). This decrease is comparableentire cell population.
Similar observations were also made in HEK293 cells. to that observed in mTOR siRNA-transfected HEK293
Figure 3. PLD1 siRNA Reduces Cell Size
COS-7 or HEK293 cells were transfected with siRNA for PLD1, GAPDH, or OligoFectamine alone (control), followed by cell size determination,
as described in Experimental Procedures. Rapamycin treatment was carried out at 100 nM for 48 hr. (A) Histograms of mean FSC-H for COS-7
cells are shown, comparing mock-transfected cells with and without rapamycin treatment (top), and with PLD1 siRNA-transfected (middle)
or GAPDH siRNA-transfected cells (bottom). (B) Size comparisons for COS-7 and HEK293 cells are shown by normalized mean FSC-H, with
that of control cells being 1. Student’s t tests were performed for comparisons with the control, and the asterisk (*) denotes p  0.01.
Current Biology
2040
is resistant to rapamycin and still sensitive to the PI3K
inhibitor wortmannin [27, 28]. As shown in Figure 5A,
the expression level of this mutant was lower than that
of wild-type S6K1 (under equal transfection conditions),
which correlated with a lower kinase activity (35% of
wild-type activity). Nonetheless, the activity of S6K1NC
was stimulated by serum and completely resistant to
rapamycin (Figure 5B). In fact, rapamycin treatment led
to a slight increase of the activity of this mutant, similar
to the observations reported by other groups [27, 28].
Importantly, the serum-stimulated S6K1NC activity
was not affected by coexpression of Cdc42T17N (Figure
5B). This Cdc42-insensitive behavior is consistent with
the notion that Cdc42 lies on the mTOR pathway. On
the other hand, Cdc42Q61L still augmented S6K1NC
activation, and this activity was rapamycin-insensitive
(Figure 5B), suggesting that the constitutively active mu-
tant of Cdc42 may activate S6K1 via an mTOR-indepen-
dent pathway. Such a pathway may or may not exist in
Figure 4. Cdc42 Activates S6K1 a physiological setting without the active mutant.
HEK293 cells were transfected with various HA-tagged Cdc42 con-
structs or empty vector (indicated at the top of graphs) together with
Myc-S6K1. Following serum starvation, the cells were stimulated by PLD1 Mediates Cdc42 Activation
serum with or without 100 nM rapamycin. The recombinant S6K1 of mTOR Signaling
was then immunoprecipitated and assayed in vitro. Recombinant We hypothesized that the activation of S6K1 by Cdc42
protein expression was confirmed by Western analysis. Relative
in vivo might be mediated by a PLD1-PA-mTOR path-activities are shown for wt Cdc42 stimulated with serum being 100%.
way. In order to test this hypothesis, we considered the
mechanism by which Cdc42 activates PLD1. Previous
studies have shown that the Rho insert region (a 13cells reported by Kim et al. [21]. The smaller degree of
size reduction by PLD1 siRNA compared to rapamycin amino acid helix unique to the Rho proteins) is specifi-
cally required for Cdc42’s (but not Rac1’s) action ontreatment in both COS-7 and HEK293 cells may reflect
the less than 100% siRNA transfection efficiency and/ PLD1 [16, 29] and is dispensable for other Cdc42-medi-
ated signaling tested so far, including activation of Pakor the incomplete elimination of PLD1 protein by siRNA.
In conclusion, it is evident that PLD1 is critically involved and JNK, and cytoskeleton rearrangements [30]. Muta-
tional analysis has identified Ser124 as a critical residuein the regulation of cell growth, consistent with its role
as an upstream regulator of mTOR signaling. in the insert region of Cdc42; a mutation to alanine at
this site abolishes Cdc42’s ability to activate PLD1 in
vitro [29]. To confirm the effect of Cdc42S124A on PLDCdc42 Activates S6K1 through mTOR
The Rho family of small G proteins activates PLD1 in activity in HEK293 cells, we coexpressed various Cdc42
proteins with recombinant PLD1 and measured totalmany cell types [10, 11]. Chou and Blenis have reported
that activated Cdc42 is a potent stimulator of S6K1 acti- cellular PLD activity. Because of the low endogenous
level of serum-stimulated PLD activity in HEK293 cells,vation [13]. We set out to investigate a potential link
between Cdc42 and PLD1 activation of mTOR signaling. expression of recombinant PLD1 was necessary to en-
sure the reliability of the PLD assays. As expected, ex-Consistent with the previous report, we found that in
HEK293 cells the expression of a constitutively active pression of the constitutively active Cdc42Q61L en-
hanced serum-stimulated PLD activity, whereas theCdc42 mutant (Q61L; GTPase-defective) increased both
the basal and the serum-stimulated activity of S6K1; dominant-negative Cdc42T17N reduced PLD activity
(Figure 6A). Consistent with the S6K1 activity data (Fig-overexpression of the wild-type Cdc42 had little effect
on S6K1 in these cells (Figure 4). Meanwhile, a dominant- ure 4), the expression of wild-type Cdc42 did not contrib-
ute significantly to the endogenous levels of PLD activitynegative mutant of Cdc42 (T17N; constitutively GDP
bound) led to a reduction in serum-stimulated S6K1 (data not shown). Because equal S6K1 protein expres-
sion among various Cdc42 cotransfections was moreactivity (Figure 4).
The activation of S6K1 requires the parallel inputs easily achieved than cotransfection with an empty vec-
tor, we used wt Cdc42 as a control in all subsequentof multiple upstream signals, the best characterized of
which are mediated by the mTOR pathway and the PI3K experiments. Importantly, Cdc42S124A inhibited PLD
activity to a similar extent as Cdc42T17N (Figure 6A). Thepathway. mTOR signaling appears to be a prerequisite
for the activation of S6K1 by other signals [2], and rapa- S124A mutation reduced Q61L’s activity toward PLD, to
a degree that was still statistically higher than the wild-mycin abolishes S6K1 activation in response to any
stimulus. Thus, it cannot be assumed that Cdc42 acts type Cdc42 (Figure 6A). Although the exact mechanism
of action by this double mutant is not clear, the datadirectly in the mTOR pathway even though rapamycin
inhibits S6K1 activation by Cdc42 (Figure 4 and [13]). implies that constitutive GTP loading of Cdc42 (Q61L)
may partially override the dependence of Rho insert forTo determine whether the Cdc42-S6K1 link is mediated
by mTOR, we examined the activation of a mutant S6K1 PLD activation.
Next, we examined the effect of the S124A mutationtruncated at both N and C termini (S6K1NC), which
Regulation of mTOR Signaling by PLD1 and Cdc42
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Figure 5. Cdc42 Acts on mTOR-Dependent
and mTOR-Independent Pathways to Regu-
late S6K1
HEK293 cells were transfected with HA-
tagged Cdc42 and Myc-tagged S6K1, fol-
lowed by treatments and kinase assays as
described in the legend for Figure 4. (A) Cells
were cotransfected with WTCdc42 and
WTS6K1 or S6K1NC. Relative S6K activi-
ties are shown for wt S6K1 stimulated by se-
rum being 100%. (B) Cells were transfected
with various Cdc42 constructs (indicated at
the top of graphs) together with S6K1NC.
Activities are normalized using that of wt
Cdc42 stimulated by serum as 100%. Recom-
binant protein expression was confirmed by
Western analysis. Asterisk indicates data that
was found to be significantly different from
that of wt Cdc42 by Student’s t test (p 0.05).
on Cdc42’s ability to activate S6K1 in vivo. As shown vation would be insensitive to the inhibitory effect
of Cdc42S124A. Indeed, when PA was used to stimu-in Figure 6B, coexpression of Cdc42S124A and S6K1
resulted in significant reduction of serum-stimulated S6K1 late HEK293 cells in lieu of serum, overexpression of
Cdc42S124A resulted in S6K1 activation similar to thatactivity, to a similar extent as expression of Cdc42T17N.
The Q61L/S124A mutant stimulated S6K1 to a degree of wild-type Cdc42 (Figure 6D), consistent with the idea
that in the presence of PA Cdc42 activation of PLD1 isthat was higher than the wild-type but lower than the
Q61L mutant; in other words, the activation of S6K1 no longer required. It is noted that Cdc42T17N exhibited
a modest inhibitory effect on PA-stimulated S6K1 activa-correlated closely with the activity of PLD1 in cells ex-
pressing the double mutant. Once again, the rapamycin- tion, which may indicate the existence of an alternative
S6K1 activation pathway.resistant S6K1NC remained active in the presence
of Cdc42S124A (Figure 6C). Taken together, these ob-
servations suggest that signaling from Cdc42 to S6K1 Discussion
in vivo is transduced specifically through PLD1.
If Cdc42 acts through PLD1 to activate S6K1, one Our previous discovery that PA mediates mitogenic acti-
vation of mTOR signaling has implicated a PA-generat-would predict that exogenous PA-stimulated S6K1 acti-
Figure 6. Cdc42 Activates S6K1 through
PLD1
(A) HA-PLD1 was coexpressed with various
Cdc42 constructs in HEK293 cells. In vivo
transphosphatidylation assays were per-
formed as described in Experimental Proce-
dures.
(B) Myc-S6K1 or (C) Myc-NCS6K1 was
coexpressed with various Cdc42 constructs.
Following serum starvation and restimulation
with or without treatment by 100 nM rapa-
mycin, recombinant S6K1 was immunopre-
cipitated and assayed in vitro.
(D) Cells transfected with Myc-S6K1 and vari-
ous Cdc42 constructs were serum starved,
followed by stimulation with 100 M PA prior
to S6K1 kinase assays. Cdc42 constructs are
labeled on the top of all graphs. Western blots
show the expression of recombinant pro-
teins. Relative activities are shown, that of
stimulated wt Cdc42 being 100% (for S6K1
activity) or one (for PLD activity). *Asterisk
indicates results of Student’s t tests, which
indicated that in (A) and (B) the activity of
S124A/Q61L was found to be significantly dif-
ferent from those of both wt and Q61L, and
in (D) the activity of T17N stimulated by PA
was significantly different from that of wt
(P  0.05).
Current Biology
2042
ing enzyme as a critical upstream regulator in the mTOR
pathway [9]. In this study, we provide strong evidence
for the involvement of PLD1 in serum-stimulated mTOR
signaling. The two mammalian PLD proteins, PLD1 and
PLD2, display distinct subcellular distributions. Whereas
PLD2 largely resides in the plasma membrane in quies-
cent cells and redistributes to vesicles near the cell
surface upon serum stimulation, PLD1 is mostly found
in intracellular membrane structures such as the ER,
Golgi, and endosomes [18, 31]. Interestingly, the vast
majority of cellular mTOR distributes between the cyto-
sol and intracellular membranes (our unpublished data
and [32]), with a small amount found in the nucleus [33].
Figure 7. A Model for mTOR Signaling to S6K1Sequence analysis has revealed multiple HEAT repeats
See text for details. An mTOR-independent Cdc42-S6K1 pathwaywithin the N-terminal two thirds of the mTOR primary
may also exist and is omitted in this diagram.
structure [34]. We have found that these putative HEAT
repeats constitute several regions that redundantly tar-
get mTOR to intracellular membranes, and that the puta- In any case, Cdc42’s action through PLD1 and its
tive PA binding FRB domain [9] is not required for mTOR direct recruitment of S6K1 need not be mutually exclu-
membrane association (M. Vilella-Bach, R. Bachmann, sive and may instead be synergistic. It is conceivable
and J.C., unpublished data). Although we have not been that the association between Cdc42 and S6K1 brings
able to detect any direct interaction between PLD1 and S6K1 to the proximity of PLD1, PA, and mTOR, and
mTOR so far, our collective findings are consistent with thus facilitates the signal relay. At the same time, full
the following model: the constitutive membrane localiza- activation of S6K1 may still require localization of S6K1
tion of mTOR confers its proximity to PLD1; upon mito- to the membrane where kinases such as PDK1 and PKC
genic stimulation, PLD1 produces PA, which then binds at the downstream of PI3K exert their functions [2]. Con-
mTOR and activates mTOR signaling. sistent with this notion, RhoA, which is incapable of
Our data do not rule out the possible involvement of binding S6K1 [13], does not significantly stimulate S6K1
PLD2 or other PA-producing enzymes in mTOR signal- activation in vivo ([13] and data not shown) even though
ing. Indeed, Chen et al. recently reported that over- it is known to activate PLD1 [10, 11]. It is also possible
expression of PLD2 led to increased S6K1 phosphoryla- that differential subcellular distribution of these small G
tion in breast cancer cells [35]. However, we did not proteins, or the involvement of scaffold proteins, deter-
observe any marked effect on S6K1 by overexpressing mines the assembly of specific pathways. For example,
PLD2 in HEK293 cells (data not shown). While different the scaffold protein Spinophilin serves to recruit the
cell types may differentially utilize the PLD pathways, Rac-GEF Tiam1, as well as S6K1, to Rac, which specifi-
aberrant localization of the recombinant protein is also cally enhances Rac activation of S6K1 and not other
a potential problem in experiments relying on overex-
effectors [36].
pression of PLD. Endogenous PLD2’s role in mTOR sig-
Interestingly, more newly emerged components of the
naling should be assessed in future investigations.
rapamycin-sensitive signaling network are found to po-Previously, Chou and Blenis have identified the small
tentially associate with cellular membranes. For instance,G proteins Cdc42 and Rac1 as upstream activators of
the interaction between Raptor and mTOR is highly sen-S6K1 [13]. S6K1 specifically interacts with GTP bound
sitive to nonionic detergent, implying the involvementCdc42/Rac1, and this interaction leads to S6K1 activa-
of membrane structures and/or lipids in maintaining thetion in vivo, but not in vitro, which has led to the pro-
Raptor-mTOR complex [7, 21]. TSC1 contains a putativeposed model that Cdc42 or Rac1 serves to recruit S6K1
transmembrane domain, and at least a fraction of theto the membrane to allow the phosphorylation and acti-
TSC1/2 complex is found to associate with membranesvation of S6K1 by a membrane bound kinase [13]. The
[37]. Rheb, the direct target of TSC1/2 [38], is farnesy-evidence we presented in this report suggests another
lated and membrane bound, and the farnesylation ofmechanism in which Cdc42 acts upstream of the PLD1-
Rheb is required for activation of S6K1 [39]. The subcel-PA-mTOR cascade that ultimately results in S6K1 acti-
lular localizations of mTOR, PLD, and Cdc42 further addvation (Figure 7). However, this linear pathway may not
to this expanding network at the membranes. It is plausi-be the sole link between Cdc42 and S6K1, as the consti-
ble that cellular membranes serve as a scaffold to bothtutively active Cdc42Q61L is capable of activating S6K1
facilitate and confer specificity to the signaling leadingin an mTOR-independent manner (Figure 5B) and
to S6K1 activation (Figure 7), although the nature of thisCdc42T17N still has a modest negative effect on S6K1
membrane structure is yet to be determined.activation with exogenous PA as the stimulus (Figure
PLD has been associated with a wide range of cellular6D). The effect of the PLD1-specific mutation S124A on
functions including vesicle trafficking, secretion, recep-Cdc42’s affinity for S6K1 would be informative. Unfor-
tor endocytosis, and cytoskeleton reorganization [18–tunately, the Cdc42-S6K1 interaction appears to be
20]. In this study, we provide the first demonstration forweak, and we have not been able to consistently observe
a direct role of PLD1 in the control of mammalian cellcoimmunoprecipitation between wt-Cdc42-GTPS or
growth (Figure 3). The involvement of PLD in tumorigen-Cdc42Q61L and wt-S6K1. This technical problem cur-
esis has been suggested by elevated PLD activity and/rently precludes our assessment of S124A’s effect on
the interaction. or increased PLD protein levels in various human cancer
Regulation of mTOR Signaling by PLD1 and Cdc42
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quences; the results of blast search revealed no significant homol-tissues and cells (e.g., [40]). Consistently, both PLD1
ogy to any other sequences in the database. The siRNAs wereand PLD2 have been shown to contribute to cell trans-
synthesized by in vitro transcription using the Silencer siRNA Con-formation [41]. Furthermore, Cdc42-mediated cell trans-
struction Kit (Ambion, Inc.) and purified following the manufacturer’s
formation has been speculated to involve PLD1 since procedures. A control siRNA targeting GAPDH was also synthesized
deletion of the insert region of Cdc42 interferes with its using materials provided by the kit.
transforming activity and PLD1 activation [29], but not
Plasmidsother identified effectors [30]. The identification of PLD1
The following constructs were previously described: pCDNA3-Myc-in the mTOR pathway provides a molecular interpreta-
S6K1 and -NCS6K1 [9]; pCGN-HA-hPLD1wild-type and K898Rtion for PLD’s oncogenic activity, as mTOR and PI3K
[43]; pKH3-HA-Cdc42wild-type, Q61L, T17N, S124A, and S124A/
signaling cooperate to constitute a major oncogenic Q61L [29].
pathway in a variety of human cancers [42]. Indeed, a
close correlation between PLD activity in human breast PLD Assay
In vivo transphosphatidylation PLD assays were performed as pre-cancer cells and their sensitivity to rapamycin has been
viously described [17, 18]. HEK293 cells were transfected with PLD1demonstrated recently [35]. It is thus reasonable to
cDNA with or without Cdc42 cDNAs for 24 hr and then labeled with 4speculate that novel anti-cancer therapeutics may de-
Ci 3H-palmitic acid in the absence of serum for 18–24 hr. The labeling
rive from synergistic targeting of PLD and mTOR. medium was then replaced with fresh medium containing 0.3%
1-butanol with or without serum, and 30 min later the total cellular
lipids were extracted and analyzed on Whatman LK5DF silica gel 150AConclusions
TLC plates following previously published protocols [17, 18].Our findings presented here demonstrate the involve-
ment of PLD1 for mitogenic activation of mTOR signal-
S6K1 Kinase Assaysing, leading to activation of S6K1. Previously reported
Endogenous or recombinant S6K1 was immunoprecipitated using
to activate S6K1 in vivo, Cdc42 appears to act on PLD1 anti-S6K1 or anti-Myc antibody, respectively. S6 kinase assays were
as one of the mechanisms to regulate mTOR signaling. carried out in the immune complex using a peptide substrate as
previously described [33].A new mitogenic cascade in the rapamycin-sensitive
signaling network has thus emerged, relaying mitogenic
Cell Size Determinationsignals through Cdc42-PLD1-PA-mTOR-S6K1 (Figure
To determine relative size of cells, an Epics XL-MCL (Coulter) flow7). Furthermore, PLD1’s essential role in regulating cell
cytometer with Summit v.3.1 (Cytomation, Inc.) software was used.
growth is revealed, highlighting the physiological signifi- COS-7 or HEK293 cells grown in 6-well plates were transfected with
cance of this novel biochemical link. PLD1 siRNA as described above. After 24 hr incubation, cells were
trypsinized and replated into 60 mm plates at 15% confluence in
Experimental Procedures DMEM containing 10% fetal bovine serum and harvested after 72
hr. Rapamycin (100 nM) was added to some of the cells at 24 hr
Antibodies and Other Reagents after replating. To harvest, cells were washed once with PBS, once
Anti-S6K1, anti-phospho-T389-S6K1, and anti-phospho-Erk were with PBS/2.5 mM EDTA, and incubated in PBS/EDTA at 37C for 5
from Cell Signaling. Anti-4E-BP1, anti-PLD1, and anti-HA (16B12) min. Cell suspensions were recovered with a pipet, centrifuged at
were from Zymed Laboratories, Upstate Biotechnologies, and 1500 rpm for 5 min, washed with PBS containing 1% FBS, and
Babco Berkeley Antibody Company, respectively. Anti-Myc 9E10.2 resuspended in PBS. Cells were fixed in 70% ethanol, washed once
and the anti-mTOR rabbit sera were generated by the Immunological with PBS/1% FBS, and incubated for 30 min with propidium iodide/
Center at University of Illinois. All secondary antibodies were from RNase A solution (10 g/mL propidium iodide in 0.76 mM sodium
Jackson Imuno-Research Labs. The anti-tubulin antibody was a citrate [pH 7.0], 250 g/mL RNase A in 10 mM Tris-Hcl, 15 mM NaCl
generous gift from Dr. Vladimir Gelfand (UIUC). Rapamycin was from [pH 7.5]). 10,000 cells were analyzed for each sample to obtain the
Calbiochem. All cell medium components were from Invitrogen. PA parameter mean forward scatter-height (FSC-H).
(1-palmitoyl-2-oleoyl-phosphatidic acid) and phosphatidylbutanol
(PtdBtOH) were from Avanti Lipids. 3H-palmitate was from Perkin Statistical Analysis
Elmer Life Sciences. The quantitative data shown throughout this report were the average
results of three or more independent experiments with standard
deviation indicated by error bars. Student’s t tests were performedCell Culture and Transfection
for all data comparisons, and significant difference was defined byHEK293 cells and COS-7 cells were grown in DMEM containing 10%
p  0.05.fetal bovine serum at 37C with 5% CO2. All transfection experiments
were performed when cells were 60%–70% confluent in 6-well
plates. Transfection of plasmids was carried out using PolyFect Acknowledgments
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assays or Western blotting. Whenever applicable, 100 nM rapamycin
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